This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Big Pharmas Don't Feel the Slowdown's Pain

A slowing economy failed to slow drug sales, with three pharmaceutical giants Wednesday all reporting strong earnings growth.

Bristol-Myers Squibb (BMY) posted first-quarter earnings that beat Wall Street estimates by a penny, while Pharmacia (PHA) and American Home Products (AHP) reported results in line with expectations. The companies said earnings growth targets were met because of strong sales of prescription drugs, despite hits taken because of negative foreign exchange factors.

Bristol-Myers Squibb

New York-based Bristol-Myers posted a 10% year-over-year jump in first-quarter earnings from continuing operations of $1.24 billion, or 63 cents per share. That compares with earnings of $1.13 billion, or 56 cents per share, in the first quarter of 2000.

The company previously announced that it plans to spin off or sell its Clairol beauty products and Zimmer orthopedic units, which are not included in the company's earnings results.

Sales from continuing operations grew 5% to $4.7 billion in the first quarter, compared with $4.5 billion from the year-ago quarter. U.S. pharmaceutical sales increased 13% while international sales fell 4%. Overseas sales would have risen 4% if not for negative foreign exchange factors, the company said.

Strong drug sale growth was led by a 31% jump in sales of the Glucophage family of drugs to treat noninsulin-dependent diabetes to $557 million, compared with the year-ago quarter.

Worldwide sales of the cholesterol-lowering drug Pravachol increased 10% to $507 million in the first quarter.

Bristol-Myers is taking a hit from generic drug competition. Sales of the anticancer drug Taxol dropped 14% to $330 million, including a 28% decrease in the U.S., where Ivax Corp. (IVX) sells a generic form of Taxol.

Generic forms of the company's anti-anxiety drug Buspar also hit the market at the end of the first quarter. Buspar sales increased 25% to $203 million in the quarter, but sales will drop now that the generic version is on the market.

Looking ahead, the drugmaker said it remains comfortable with current consensus estimates of 2001 earnings of $2.41 per share.

Shares in Bristol-Myers were up $1.10, or 2%, to $56 in recent trading.


The Peapack, N.J.-based drug company said first-quarter profits on an adjusted basis rose 19% to $423 million, or 32 cents per share, compared with the year-ago quarter.

Results were adjusted to exclude about $145 million in restructuring and merger-related charges related to the company's purchase of Monsanto (MON) last year.

Total sales were $4.5 billion, an 8% jump over the first quarter 2000. Net sales for Pharmacia's pharmaceutical business rose 13% to $3.2 billion. Agricultural sales, primarily the Monsanto business, fell 1% to $1.3 billion

Drug sales were led by $649 million in first quarter sales for the arthritis drug Celebrex, a 24% increase over the year-ago quarter. Sales of Ambien, a sleeping aid, rose 114% to $215 million. Glaucoma drug Xalatan posted a 24% jump in sales from the same quarter last year to $200 million.

On its conference call, Pharmacia executives said future guidance remains unchanged, with full-year 2001 earnings growth of about 20% and 15% to 17% growth in second-quarter earnings from the year-ago quarter.

Wall Street is looking for the company to post second-quarter and full-year 2001 earnings of 63 cents per share and $1.75 per share, respectively.

Shares in Pharmacia were up 54 cents, or just over 1%, to $48.55 per share in recent trading.

American Home Products

The Madison, N.J.-based company said first-quarter profits rose 16% to $733.6 million, or 55 cents per share, compared with $634.9 million, or 48 cents per share, in the prior year.

Worldwide net revenue rose 8% to $3.45 billion in the first quarter, compared with one year ago. Worldwide human drug sales increased 12%, primarily due to higher sales of Prevnar, the company's pneumococcal vaccine, as well as the ulcer drug Protonix, the Premarin line of female hormone replacements and Effexor XR, used to treat depression.

Sales of the company's oral contraceptives and its meningitis drug were lower in the first quarter, and the company took a 3% negative hit on overseas sales due to unfavorable foreign exchange rates.

On its conference call, American Home executives said they were sticking to forecasts for 2001 earnings of $2.15 per share to $2.20 per share. Analysts are expecting 2001 earnings of $2.19 per share, according to Thompson Financial/First Call.

The company also said the $12.25 billion already set aside to settle its diet drug litigation should be enough to handle all claims. In the first quarter, the company paid out $4.1 billion in liabilities stemming from the recall of its appetite suppressants Pondimin and Redux, best known as the fen-phen diet drug combo.

American Home shares were up $1.34, or 2.4%, to $55.69 in recent trading.

Interested in drilling deeper on biotech? Sign up for a special one-day conference to hear the most knowledgeable financial experts in the biotech sector discuss the winning technologies, most promising treatments and best investment opportunities.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs